Century Therapeutics (IPSC) Insider Trading & Ownership $1.21 -0.03 (-2.42%) (As of 11/22/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Century Therapeutics (NASDAQ:IPSC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.80%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$197,649.70 Get IPSC Insider Trade Alerts Want to know when executives and insiders are buying or selling Century Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address IPSC Insider Buying and Selling by Quarter Ad DTII've got news for you… Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman Century Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/4/2024Adrienne FaridInsiderSell1,033$1.23$1,270.59 11/4/2024Douglas CarrSVPSell283$1.23$348.09 8/5/2024Adrienne FaridInsiderSell1,073$1.83$1,963.59 8/5/2024Douglas CarrSVPSell289$1.83$528.87 7/26/2024Gregory RussottiInsiderSell586$2.50$1,465.00 7/23/2024Gregory RussottiInsiderSell200$2.50$500.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/20/2024Gregory RussottiInsiderSell5,000$2.84$14,200.00 6/5/2024Gregory RussottiInsiderSell5,000$3.00$15,000.00 5/6/2024Gregory RussottiInsiderSell5,000$3.12$15,600.00 5/3/2024Adrienne FaridInsiderSell913$3.11$2,839.43 5/3/2024Douglas CarrSVPSell257$3.11$799.27 4/22/2024Gregory RussottiInsiderSell5,000$3.10$15,500.00 3/7/2024Adrienne FaridInsiderSell22,831$5.14$117,351.34 2/5/2024Adrienne FaridInsiderSell2,035$3.84$7,814.40 2/5/2024Douglas CarrSVPSell643$3.84$2,469.12 (Data available from 1/1/2013 forward) IPSC Insider Trading Activity - Frequently Asked Questions Who is on Century Therapeutics's Insider Roster? The list of insiders at Century Therapeutics includes Adrienne Farid, Douglas Carr, Gregory Russotti, Luis Borges, and Versant Venture Capital Vi, L.. Learn more on insiders at IPSC. What percentage of Century Therapeutics stock is owned by insiders? 6.80% of Century Therapeutics stock is owned by insiders. Learn more on IPSC's insider holdings. Which Century Therapeutics insiders have been selling company stock? The following insiders have sold IPSC shares in the last 24 months: Adrienne Farid ($131,239.35), Douglas Carr ($4,145.35), Gregory Russotti ($62,265.00), and Luis Borges ($295,201.67). How much insider selling is happening at Century Therapeutics? Insiders have sold a total of 129,356 Century Therapeutics shares in the last 24 months for a total of $492,851.37 sold. Century Therapeutics Key ExecutivesMr. Brent Pfeiffenberger M.B.A.Pharm.D., CEO & DirectorDr. Adrienne Farid Ph.D. (Age 62)COO & Head of Early Development Compensation: $670.29kDr. Gregory Russotti Ph.D. (Age 57)Chief Technology & Manufacturing Officer Compensation: $852.56kMr. Douglas Carr CPAInterim Principal Financial Officer, Senior VP of Finance & Operations and Secretary2 recent tradesMr. Kenneth J. Dow J.D.Senior VP of General CounselDr. Shane Williams Ph.D.Chief People OfficerDr. Hyam I. Levitsky M.D. (Age 66)President of Research & Development Compensation: $502.12kMichael Naso Ph.D.Senior VP of Cell EngineeringDr. Nick Trede M.D.Ph.D., Senior VP & Head of Clinical Development More Insider Trading Tools from MarketBeat Related Companies Invivyd Insider Transactions AlloVir Insider Transactions bluebird bio Insider Transactions Kronos Bio Insider Transactions Nkarta Insider Transactions Fate Therapeutics Insider Transactions Aquestive Therapeutics Insider Transactions Canopy Growth Insider Transactions KalVista Pharmaceuticals Insider Transactions Akebia Therapeutics Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:IPSC) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
